OGN•A study of 16,322 veterans who switched from Humira to Hadlima found few returned to Humira and similar treatment adherence. Estimated VA savings totaled $132 million, with average first-year pharmacy costs falling $8,100 per patient.
Organon will present real-world findings on November 9, 2026, at the ACR annual meeting. The study covered 16,322 veterans who switched from Humira to Hadlima; few returned to Humira, while treatment adherence remained similar. Estimated VA savings totaled $132 million, and average pharmacy costs fell $8,100 per patient in the first year after the switch.
Hadlima exclusively replaced Humira on the VA’s national formulary in 2024.
